Lefamulin

Lefamulin (BC-3781) is an orally active antibiotic. Lefamulin inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. Lefamulin has anti-inflammatory activity. Lefamulin can be used in the research of bacterial infections, such as bacterial pneumonia[1].

Product Specifications

CAS Number

[1061337-51-6]

Product Name Alternative

BC-3781

UNSPSC

12352211

Hazard Statement

H315, H319, H320

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/lefamulin.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@H]1[C@]23[C@](C(CC3)=O)([H])[C@]([C@@H](C[C@](C)([C@H]1O)C=C)OC(CS[C@H]4[C@@H](C[C@@H](CC4)N)O)=O)([C@@H](CC2)C)C

Molecular Formula

C28H45NO5S

Molecular Weight

507.73

Precautions

H315, H319, H320

References & Citations

[1]Veve MP, et al. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018 Sep;38 (9) :935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20.|[2]Susanne Paukner, et al. Antimicrob Agents Chemother. 2018 Apr 26;62 (5) :e02380-17. |[3]Ken B Waites, et al. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob Agents Chemother. 2017 Jan 24;61 (2) :e02008-16. |[4]Michael Hafner, et al. Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model. PLoS One. 2021 Sep 29;16 (9) : e0237659. https://pubmed.ncbi.nlm.nih.gov/34587166/|[5]Wolfgang W Wicha, et al. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumonia. J Antimicrob Chemother. 2019 Apr 1;74 (Suppl 3) :iii11-iii18.